Denali Therapeutics Inc [DNLI] stock is trading at $23.02, up 2.22%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DNLI shares have gain 4.64% over the last week, with a monthly amount drifted -1.33%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Denali Therapeutics Inc [NASDAQ: DNLI] stock has seen the most recent analyst activity on December 13, 2023, when Citigroup initiated its Buy rating and assigned the stock a price target of $32. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $38 on September 06, 2023. SVB Securities initiated its recommendation with a Outperform and recommended $50 as its price target on January 30, 2023. In a note dated November 02, 2022, BTIG Research upgraded an Buy rating on this stock but restated the target price of $38.
Denali Therapeutics Inc [DNLI] stock has fluctuated between $14.56 and $25.24 over the past year. Currently, Wall Street analysts expect the stock to reach $91 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $23.02 at the most recent close of the market. An investor can expect a potential return of 295.31% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
Denali Therapeutics Inc [NASDAQ:DNLI] reported sales of 1.27M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.03% with Operating Profit Margin at 1.63%, Pretax Profit Margin comes in at 1.38%, and Net Profit Margin reading is 1.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.34 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.47 points at the first support level, and at 21.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.33, and for the 2nd resistance point, it is at 23.64.
Ratios To Look Out For
For context, Denali Therapeutics Inc’s Current Ratio is 12.46. As well, the Quick Ratio is 12.46, while the Cash Ratio is 1.0. Considering the valuation of this stock, the price to sales ratio is 2594.92, the price to book ratio is 2.38.
Transactions by insiders
Recent insider trading involved Ho Carole, Officer, that happened on Aug 13 ’24 when 2337.0 shares were purchased. Officer, Schuth Alexander O. completed a deal on Aug 13 ’24 to buy 2272.0 shares. Meanwhile, Director Krognes Steve E. sold 30000.0 shares on Jul 01 ’24.
